Quantcast

Industry news that matters to you.  Learn more

Archives for February 2012

HistoRx Earns Patent on Quantitative Immunoassay Optimization

HistoRx, the leader in quantitative immunohistochemistry (IHC), advances its proprietary position in measurement of biomarkers in tissue through today’s issuance of US Patent 8,121,365 protecting the company’s “Methods and systems for determining optimal dilution of a reagent.” As the first in what HistoRx expects will be a series of broadening patents pertaining to its quantitative methodology, this patent protects the company’s capabilities in optimizing antibody concentration for quantitative immunoassays, methods required to generate high-quality reproducible clinical diagnostic results that precisely relate to biomarker concentrations in tissue sections.

Biogen Idec to Acquire Stromedix

Biogen Idec (NASDAQ: BIIB) and Stromedix, Inc. recently announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc., a privately held biotechnology company focused on innovative therapies for fibrosis and organ failure. Under the terms of the agreement, Biogen Idec will make an upfront cash payment of $75 million and additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.

Covance Scientists to Present at the Molecular Med Tri-Con

Scientists from Covance Discovery and Translational Services will be showcasing their company’s R&D capabilities, talent and technologies in biomarkers, discovery services, genomics and proteomics to over 3,000 participants at the 2012 Molecular Med Tri-Con this week in San Francisco, CA.

Ingenuity Variant Analysis Enables Rapid Identification of Causal Variants From Human Resequencing Studies

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced the general availability of Ingenuity Variant Analysis, a web application designed to help researchers studying human disease rapidly identify causal variants from human resequencing data. Researchers can quickly and reliably take a list of millions of variants down to the most compelling set of variants for follow-up study and analysis.

SOMAscan Technology Presented at 2012 AAAS Meeting

“Prediction” is only part of what is needed to realize the promise of personalized medicine: It is perhaps more critical to detect the early onset of disease in real time, when it is most likely to be successfully treated. Dr. Larry Gold, CEO of SomaLogic and Professor at the University of Colorado Boulder, presented a breakthrough technology that promises to provide such sensitive and early detection, and ultimately transform the practice of medicine. His talk, Unlocking Biomarker Discovery, was given at a special Session on “Predictive Medicine” on February 17, 2012, at the American Association for the Advancement of Science (AAAS) annual meeting in Vancouver, Canada.